Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2021

View Archived Issues

UCART-19 shows antileukemic activity in heavily pretreated pediatric and adult patients

JMX-0207 inhibits Zika virus both in vitro and in vivo

Inhaled phage therapy YPT-01 enters phase I/II trial to treat P. aeruginosa in cystic fibrosis

FDA clears IND for phase I study of DA-01 in advanced Parkinson's disease

CARs with switches

FDA issues clinical hold letter related to an IND for NL-201

Positive phase IIb data presented for DBI-001 in tinea pedis

Dana-Farber Cancer Institute patents EGFR allosteric inhibitors

Bristol Myers Squibb discloses new FPR2 agonists

Calithera Biosciences presents CD73 inhibitors

Indian researchers patent new lipoxygenase inhibitors

Antibodies target fibrotic and autoimmune diseases

CAR-MICA/B immunotherapy controls hematopoietic and solid tumor progression in vivo

AMMS synthesizes new adenosine A2A receptor agonists

Discovery of non-sugar-derived OGA inhibitors for neurodegenerative disorders

U.K. approval of COVID-19 Vaccine Moderna

Tocilizumab to be used in U.K. for ICU patients with COVID-19

Open-label study data show patients treated with LB-1148 had shorter hospital stay

Preclinical data presented for CD30-targeting CAR T cells as lymphoma immunotherapy

Ultragenyx updates gene therapy program progress

E.U. approval for Xofluza for treatment and postexposure prophylaxis of influenza

Celon reports topline phase II data on Falkieri in bipolar depression

Ideaya submits IND for phase I evaluation of MAT2A inhibitor IDE-397

Phase II TRAILBLAZER-ALZ trial of donanemab in Alzheimer's meets primary endpoint

Cara opens phase II trial of oral difelikefalin for notalgia paresthetica pruritus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...